念珠菌血症治疗期间因FKS1突变导致光滑念珠菌敏感性降低。
Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.
作者信息
Cleary John D, Garcia-Effron Guillermo, Chapman Stanley W, Perlin David S
机构信息
Mycotic Research Center, University of Mississippi Schools of Pharmacy and Medicine, Jackson, Mississippi 39216, USA.
出版信息
Antimicrob Agents Chemother. 2008 Jun;52(6):2263-5. doi: 10.1128/AAC.01568-07. Epub 2008 Mar 31.
Abstract
We describe a case of recurring Candida glabrata infection in a 68-year-old African-American female on caspofungin therapy. The initial isolate was susceptible, but isolates recovered during following relapses were not. All isolates were clonal, and high-MIC strains contained a mutation in the highly conserved hot spot 1 region of Fks1p.
摘要
我们描述了一例接受卡泊芬净治疗的68岁非裔美国女性复发性光滑念珠菌感染病例。最初分离出的菌株敏感，但后续复发时分离出的菌株不敏感。所有分离株均为克隆性，高MIC菌株在Fks1p高度保守的热点1区域存在突变。
相似文献
1
Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.
Antimicrob Agents Chemother. 2008 Jun;52(6):2263-5. doi: 10.1128/AAC.01568-07. Epub 2008 Mar 31.
2
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
Clin Infect Dis. 2013 Jun;56(12):1724-32. doi: 10.1093/cid/cit136. Epub 2013 Mar 13.
3
The Gastrointestinal Tract Is a Major Source of Echinocandin Drug Resistance in a Murine Model of Candida glabrata Colonization and Systemic Dissemination.
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01412-17. Print 2017 Dec.
4
Antifungal resistance does not necessarily affect Candida glabrata fitness.
J Chemother. 2014 Feb;26(1):32-6. doi: 10.1179/1973947813Y.0000000100. Epub 2013 Dec 6.
5
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.
Antimicrob Agents Chemother. 2008 Oct;52(10):3783-5. doi: 10.1128/AAC.00473-08. Epub 2008 Aug 1.
6
FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.
Antimicrob Agents Chemother. 2010 Dec;54(12):5042-7. doi: 10.1128/AAC.00836-10. Epub 2010 Sep 13.
7
Antifungal drug susceptibility, molecular basis of resistance to echinocandins and molecular epidemiology of fluconazole resistance among clinical Candida glabrata isolates in Kuwait.
Sci Rep. 2020 Apr 10;10(1):6238. doi: 10.1038/s41598-020-63240-z.
8
Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common candida species.
Antimicrob Agents Chemother. 2013 Jan;57(1):177-82. doi: 10.1128/AAC.01382-12. Epub 2012 Oct 22.
9
In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection.
Antimicrob Agents Chemother. 2014 Jul;58(7):3646-9. doi: 10.1128/AAC.02666-13. Epub 2014 Apr 14.
10
Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient.
Antimicrob Agents Chemother. 2010 Mar;54(3):1360-2. doi: 10.1128/AAC.01138-09. Epub 2009 Dec 28.
引用本文的文献
1
The yEvo Mutation Browser: Enhancing student understanding of experimental evolution and genomics through interactive data visualization.
bioRxiv. 2025 Jul 22:2025.07.18.665463. doi: 10.1101/2025.07.18.665463.
2
Whole genome sequencing analysis of Candida glabrata isolates collected from patients with selected drug-resistant candidiasis hospitalized in Eastern Poland.
Folia Microbiol (Praha). 2025 Jul 14. doi: 10.1007/s12223-025-01298-w.
3
: Multidrug Resistance and Increased Virulence in a Major Opportunistic Fungal Pathogen.
Curr Fungal Infect Rep. 2012 Jun;6(3):154-164. doi: 10.1007/s12281-012-0091-0.
4
Genomic description of acquired fluconazole- and echinocandin-resistance in patients with serial isolates.
J Clin Microbiol. 2024 Feb 14;62(2):e0114023. doi: 10.1128/jcm.01140-23. Epub 2024 Jan 24.
5
Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Species.
Cells. 2023 Nov 19;12(22):2655. doi: 10.3390/cells12222655.
6
Antifungal Susceptibility Testing: A Primer for Clinicians.
Open Forum Infect Dis. 2021 Sep 9;8(11):ofab444. doi: 10.1093/ofid/ofab444. eCollection 2021 Nov.
7
Recent Trends in the Epidemiology of Fungal Infections.
Infect Dis Clin North Am. 2021 Jun;35(2):237-260. doi: 10.1016/j.idc.2021.03.001.
8
Rezafungin-Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins.
J Fungi (Basel). 2020 Nov 1;6(4):262. doi: 10.3390/jof6040262.
9
The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens.
J Fungi (Basel). 2020 Aug 18;6(3):138. doi: 10.3390/jof6030138.
10
Low level of antifungal resistance of Candida glabrata blood isolates in Turkey: Fluconazole minimum inhibitory concentration and FKS mutations can predict therapeutic failure.
Mycoses. 2020 Sep;63(9):911-920. doi: 10.1111/myc.13104. Epub 2020 Aug 5.
本文引用的文献
1
Resistance to echinocandin-class antifungal drugs.
Drug Resist Updat. 2007 Jun;10(3):121-30. doi: 10.1016/j.drup.2007.04.002. Epub 2007 Jun 13.
2
Acquired resistance to echinocandins in Candida albicans: case report and review.
J Antimicrob Chemother. 2007 Jun;59(6):1076-83. doi: 10.1093/jac/dkm095. Epub 2007 Apr 27.
3
Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase.
Antimicrob Agents Chemother. 2007 May;51(5):1876-8. doi: 10.1128/AAC.00067-07. Epub 2007 Feb 26.
4
Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility.
Antimicrob Agents Chemother. 2006 Aug;50(8):2892-4. doi: 10.1128/AAC.00349-06.
5
Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.
Antimicrob Agents Chemother. 2006 Jul;50(7):2522-4. doi: 10.1128/AAC.00148-06.
6
Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin.
Pharmacotherapy. 2006 Jun;26(6):877-80. doi: 10.1592/phco.26.6.877.
7
In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.
J Clin Microbiol. 2006 Mar;44(3):760-3. doi: 10.1128/JCM.44.3.760-763.2006.
8
Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient.
Clin Infect Dis. 2006 Apr 1;42(7):938-44. doi: 10.1086/500939. Epub 2006 Feb 27.
9
Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.
J Antimicrob Chemother. 2006 Apr;57(4):705-8. doi: 10.1093/jac/dkl022. Epub 2006 Feb 7.
10
Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature.
Med Mycol. 2005 Sep;43(6):559-64. doi: 10.1080/13693780500220415.
Zotero 插件